GSE172182
KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression
Epigenetics is critical for cell fate decision and contributes greatly to cancer initiation and development. However, the underlying mechanisms are still largely elusive, thus impeding the effective targeting of histone deacetylases (HDACs) for clinical cancer therapy. Here, We used RNA-seq to study potential targets of HDAC inhibitors for breast cancer therapy. And we performed RNA-seq assays in the MDA-MB-231 cell line treated separately with three HDAC inhibitors TSA, TDPA, FK228. Overall design: MDA-MB-231 cells were treated separately with three HDAC inhibitors TSA, TDPA, FK228 for 48 hours. Total RNA was extracted using TRIzol Reagent (Invitrogen-Life Technologies, Waltham, Massachusetts, USA) following the manufacturer's instructions. The following sequencing work using these RNA samples were performed on the BGISeq500 platform (BGI-Shenzhen, Shenzhen, Guangdong, China) by BGI-Shenzhen (Shenzhen, Guangdong, China).